03014nam 2200865z- 450 991055710720332120231214132928.0(CKB)5400000000040975(oapen)https://directory.doabooks.org/handle/20.500.12854/69370(EXLCZ)99540000000004097520202105d2020 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarriermTOR Signaling in Metabolism and CancerBasel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20201 electronic resource (204 p.)3-03943-553-1 3-03943-554-X The mechanistic/mammalian target of rapamycin (mTOR), a serine/threonine kinase, is a central regulator for human physiological activity. Deregulated mTOR signaling is implicated in a variety of disorders, such as cancer, obesity, diabetes, and neurodegenerative diseases. The papers published in this Special Issue summarize the current understanding of the mTOR pathway and its role in the regulation of tissue regeneration, regulatory T cell differentiation and function, and different types of cancer including hematologic malignancies, skin, prostate, breast, and head and neck cancer. The findings highlight that targeting mTOR pathway is a promising strategy to fight against certain human diseases.MedicinebicsscmTORhistone deacetylaseprostate cancerintegrinsadhesioninvasioncell metabolismT cellsFoxp3Acute Lymphoblastic leukemiatargeted therapymetabolismcell signallingmTOR signallinghead and neck cancermutant genesbiomarkerstargeted therapiesclinical trialscancersinhibitorsphotodynamic therapyPI3KAktskin cancersphytochemicalsmelanomabasal cell carcinomasquamous cell carcinomaMerkel cell carcinomaTNBCeribulinPI3K/AKT/mTOReverolimuscombinationsynergymTOR signalingtissue regenerationneuronmuscleliverintestinehematologic malignanciesregulatory T cellstumorMedicineHuang Shileedt1325337Huang ShileothBOOK9910557107203321MTOR Signaling in Metabolism and Cancer3036762UNINA